Comment évaluer la réponse thérapeutique d'un gliome en pratique

Evaluating tumor response (and non-response) in patients with glioma is a fundamental element of patient management, both in terms of clinical research but also in routine practice. For therapeutic trials, it is of course essential to evaluate the impact of new treatments, using a reliable method. Tumor response is classically determined clinically, and with imaging. For MRI, morphology is the only recognized standard, but can be missing. Multimodal imaging data can provide additional information often useful for therapeutic decision-making. However, the exact role for these methods and their degree of validity for the definition of prognosis and response remain unclear. It is not uncommon to observe discordance between the clinical observation and the imaging data. Yet a therapeutic decision must be made…